secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxcyte, Inc. (PCVX)
CIK:        0001649094
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001193125-25-067901
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxcyte reports positive VAX-24 infant Phase 2 topline; selects mid dose; announces VAX-XL
--------------------------------------------------------------------------------

- VAX-24 well-tolerated; safety similar to Prevnar 20; no related serious adverse events.
- Mid dose (2.2mcg) met non-inferiority criteria on seroconversion for 20 of 24 serotypes; dose-dependent responses with little carrier suppression.
- Four VAX-24-unique serotypes met all target criteria at all doses evaluated.
- Company selects mid dose for optimized formulation; plans infant Phase 3 with VAX-24 or VAX-31 pending VAX-31 data (mid-2026).
- Announces VAX-XL, third-generation PCV candidate designed to provide broadest coverage PCV in development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649094/000119312525067901/0001193125-25-067901-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649094/000119312525067901/d848914d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-067901

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer